[go: up one dir, main page]

PL3435996T3 - Elafibranor do zastosowania w leczeniu pierwotnego zapalenia dróg żółciowych - Google Patents

Elafibranor do zastosowania w leczeniu pierwotnego zapalenia dróg żółciowych

Info

Publication number
PL3435996T3
PL3435996T3 PL17713332.9T PL17713332T PL3435996T3 PL 3435996 T3 PL3435996 T3 PL 3435996T3 PL 17713332 T PL17713332 T PL 17713332T PL 3435996 T3 PL3435996 T3 PL 3435996T3
Authority
PL
Poland
Prior art keywords
elafibranor
treatment
primary biliary
biliary cholangitis
cholangitis
Prior art date
Application number
PL17713332.9T
Other languages
English (en)
Inventor
Rémy HANF
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of PL3435996T3 publication Critical patent/PL3435996T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
PL17713332.9T 2016-03-31 2017-03-30 Elafibranor do zastosowania w leczeniu pierwotnego zapalenia dróg żółciowych PL3435996T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305381 2016-03-31
PCT/EP2017/057634 WO2017167935A1 (en) 2016-03-31 2017-03-30 Methods of treatment of cholestatic diseases

Publications (1)

Publication Number Publication Date
PL3435996T3 true PL3435996T3 (pl) 2025-07-28

Family

ID=55661352

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17713332.9T PL3435996T3 (pl) 2016-03-31 2017-03-30 Elafibranor do zastosowania w leczeniu pierwotnego zapalenia dróg żółciowych

Country Status (29)

Country Link
US (1) US11185519B2 (pl)
EP (3) EP3435996B1 (pl)
JP (1) JP7010836B2 (pl)
KR (1) KR102338085B1 (pl)
CN (2) CN109152756B (pl)
AU (1) AU2017242819B2 (pl)
CA (1) CA3018132C (pl)
DK (1) DK3435996T3 (pl)
EA (1) EA038386B1 (pl)
ES (1) ES3030999T3 (pl)
FI (2) FI3435996T3 (pl)
HR (1) HRP20250776T1 (pl)
HU (2) HUE071511T2 (pl)
IL (2) IL261935B2 (pl)
LT (2) LT3435996T (pl)
MD (1) MD3435996T2 (pl)
MX (2) MX2021015783A (pl)
NL (1) NL301342I2 (pl)
NO (1) NO2025045I1 (pl)
NZ (1) NZ785185A (pl)
PH (1) PH12018502056B1 (pl)
PL (1) PL3435996T3 (pl)
PT (1) PT3435996T (pl)
RS (1) RS66930B1 (pl)
SG (1) SG11201808222RA (pl)
SI (1) SI3435996T1 (pl)
SM (1) SMT202500241T1 (pl)
WO (1) WO2017167935A1 (pl)
ZA (1) ZA201807084B (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013063526A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
EA030839B1 (ru) 2011-10-28 2018-10-31 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
EA201991990A1 (ru) * 2017-02-24 2020-04-07 Женфит Фармацевтические композиции для комбинированной терапии
EP3710425A1 (en) * 2017-11-16 2020-09-23 Teva Pharmaceuticals International GmbH Solid state forms of elafibranor
WO2019186410A1 (en) * 2018-03-27 2019-10-03 Lupin Limited Solid forms of elafibranor and processes thereof
WO2020074737A1 (en) * 2018-10-11 2020-04-16 Centre National De La Recherche Scientifique Treatment of diseases associated with biliary system destruction
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
AU2020221834B2 (en) * 2019-02-12 2025-10-23 Mirum Pharmaceuticals, Inc. Genotype and dose-dependent response to an ASBTI in patients with bile salt export pump deficiency
EP3937906A1 (en) * 2019-03-13 2022-01-19 Novartis AG Pharmaceutical composition
US12208087B2 (en) * 2019-04-09 2025-01-28 Genfit Combination of nitazoxanide and elafibranor for the treatment of immune diseases or inflammation
CN114375193B (zh) 2019-09-12 2024-05-14 拓臻制药公司 甲状腺激素受体β激动剂化合物
CN110548118B (zh) * 2019-10-21 2021-09-14 江苏省中医院 一种具有防治原发性胆汁性胆管炎的中药复方及其制备方法与应用
BR112022015800A2 (pt) * 2020-02-10 2022-10-11 Genfit Tratamento de colangite biliar primária com elafibranor
BR112022015807A2 (pt) * 2020-02-10 2023-03-14 Genfit Polimorfos de elafibranor
MX2022014364A (es) * 2020-05-18 2022-12-15 Genfit Elafibranor para el tratamiento de la colangitis esclerosante primaria.
AU2021332217A1 (en) 2020-08-25 2023-05-11 Eli Lilly And Company Polymorphs of an ssao inhibitor
CN115884765A (zh) * 2020-08-26 2023-03-31 基恩菲特公司 用于治疗原发性胆汁性胆管炎的组合物和方法
JP2025517398A (ja) * 2022-05-19 2025-06-05 タイラ・バイオサイエンシーズ・インコーポレイテッド Pparアゴニスト及びfgfr4阻害剤による治療
US12296050B2 (en) 2023-10-05 2025-05-13 Mirum Pharmaceuticals, Inc. Pharmaceutical compositions comprising maralixibat and uses thereof
WO2025075624A1 (en) * 2023-10-05 2025-04-10 Mirum Pharmaceuticals, Inc. Pharmaceutical compositions comprising maralixibat and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2841900B1 (fr) 2002-07-08 2007-03-02 Genfit S A Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
US20070197606A1 (en) 2006-02-22 2007-08-23 Burczynski Frank J Use of ppar agonists as anti-oxidants
DK2641596T3 (en) * 2009-11-26 2018-08-06 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for the treatment of liver disorders
ES2905872T3 (es) * 2015-02-06 2022-04-12 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapia combinada
EA201991990A1 (ru) * 2017-02-24 2020-04-07 Женфит Фармацевтические композиции для комбинированной терапии

Also Published As

Publication number Publication date
NL301342I2 (nl) 2025-11-10
JP2019510046A (ja) 2019-04-11
CN109152756B (zh) 2022-05-17
HUE071511T2 (hu) 2025-09-28
IL261935B2 (en) 2024-09-01
EP4233910A2 (en) 2023-08-30
MX2021015783A (es) 2022-12-09
LT3435996T (lt) 2025-06-25
WO2017167935A1 (en) 2017-10-05
ES3030999T3 (en) 2025-07-03
SMT202500241T1 (it) 2025-07-22
EP4559481A2 (en) 2025-05-28
EP4233910A3 (en) 2024-01-17
CN114796237A (zh) 2022-07-29
NO2025045I1 (no) 2025-09-30
NZ785185A (en) 2024-11-29
MX388863B (es) 2025-03-20
SG11201808222RA (en) 2018-10-30
EA201892202A1 (ru) 2019-03-29
RS66930B1 (sr) 2025-07-31
BR112018069023A2 (pt) 2019-01-29
LTPA2025535I1 (pl) 2025-10-10
CA3018132C (en) 2024-02-13
JP7010836B2 (ja) 2022-01-26
EA038386B1 (ru) 2021-08-19
HUS2500039I1 (hu) 2025-10-28
KR20180126574A (ko) 2018-11-27
AU2017242819B2 (en) 2022-06-30
EP3435996A1 (en) 2019-02-06
EP4559481A3 (en) 2025-12-10
NZ746570A (en) 2024-11-29
US11185519B2 (en) 2021-11-30
ZA201807084B (en) 2019-06-26
CN109152756A (zh) 2019-01-04
AU2017242819A1 (en) 2018-10-11
KR102338085B1 (ko) 2021-12-10
IL261935A (en) 2018-10-31
PT3435996T (pt) 2025-05-13
DK3435996T3 (da) 2025-07-21
PH12018502056A1 (en) 2019-07-01
CA3018132A1 (en) 2017-10-05
FIC20250032I1 (sv) 2025-09-26
MD3435996T2 (ro) 2025-09-30
PH12018502056B1 (en) 2023-08-02
IL311687A (en) 2024-05-01
CN114796237B (zh) 2024-02-23
IL261935B1 (en) 2024-05-01
EP3435996B1 (en) 2025-04-30
FI3435996T3 (fi) 2025-06-11
SI3435996T1 (sl) 2025-08-29
US20190111012A1 (en) 2019-04-18
MX2018011738A (es) 2019-06-24
HRP20250776T1 (hr) 2025-08-29

Similar Documents

Publication Publication Date Title
PL3435996T3 (pl) Elafibranor do zastosowania w leczeniu pierwotnego zapalenia dróg żółciowych
GB201614522D0 (en) Use of cannabinoids in the treatment of multiple myeloma
ZA201903649B (en) Treatment for primary biliary cholangitis
ZA201707303B (en) Compositions and methods for the treatment of immunodeficiency
SMT202100468T1 (it) 24-idrossisteroli sostituiti in posizione 11 per l'uso nel trattamento delle condizioni correlate all'nmda
ZA201700916B (en) Heterobicyclic compounds and their use for the treatment of tuberculosis
SI3331610T1 (sl) Sredstva za uporabo pri zdravljenju gliomov
PT3160464T (pt) 6-hidroxibuspirona para uso no tratamento de transtornos do movimento
HUS2400045I1 (hu) Delgocitinib alkalmazása krónikus kézekcéma kezelésére
SMT202200471T1 (it) Seladelpar per il trattamento della colangite biliare primitiva
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
IL246855A0 (en) Materials for use in the treatment of retinitis
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
IL269121A (en) Usl-311 for use in the treatment of cancer
PT3548006T (pt) Composição para utilização no tratamento de alterações intestinais
IL252493B (en) Compounds for use in the prevention or treatment of cancer
HUE058845T2 (hu) Nem biokonvertibilis C3-szubsztituált pregnenolon-származékok szerhasználati zavarok kezelésében történõ alkalmazásra
ZA201408464B (en) Composition for the use in treatment of asthma